
    
      A total of 40 evaluable healthy male subjects will be enrolled in this study.The subjects
      will be divided into two groups, A and B, with 20 people in each group.

      In the itraconazole study (Group A), patients received single-dose SH-1028 200 mg on Days 1
      and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.

      In the rifampicin study (Group B), patients received SH-1028 200mg once daily on Days 1 and
      14 and rifampicin 600 mg once daily on Days 8-16.
    
  